Needle-Free Diabetes Care Market Anticipated to Reach Over 7.5% CAGR till 2023 | Observes MRFR

Market Research Future's Needle-Free Diabetes Care Market report highlights the competitive landscape by elaborating on the current mergers and acquisitions, Upcoming Opportunities, and venture funding that took place in the Needle-Free Diabetes Care industry in the recent past.

The Needle-Free Diabetes Care Market is segmented on the basis of devices types into treatment devices and diagnostic devices. Treatment devices are further segmented into insulin jet injector, insulin pen, insulin inhaler, and insulin patch & pump. Diagnostic devices are also further segmented into continuous glucose monitoring and instant glucose monitoring. On the basis of treatment type, the market is segmented into oral insulin, inhaled insulin, insulin patch and others. On the basis of applications, the market is segmented into insulin delivery and others. On the basis of end users, the market is segmented into diagnostic centers, hospitals & clinics, and other.

To Get Sample PDF Copy of Report visit

Needle-Free Diabetes Care Market - Sketch

Diabetes is a group of metabolic disorders, which is caused by insulin deficiency. Needle-free is a modern technique for administration of the medication to the patient. According to the International Diabetes Federation, about 420 million adult population was suffering from diabetes in 2016, which is increasing at the rate of 8.4% per year and is expected to reach 625 million by 2040. Increasing diabetic population is the major driving factor for the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market.

According to International Diabetes Federation, diabetes is becoming one of the major diseases because about 420 million adults of the total global population had diabetes in 2016. On account of lack of effective treatment for this disorder, many manufacturers are continuously trying to develop new drugs and more convenient drug delivery devices. Increasing diabetic population across the globe is the main reason for the development of the global Needle-Free Diabetes Care market. Moreover, increasing healthcare expenditure, increasing demand for the better and convenient devices, and development in healthcare infrastructure have contributed to the growth of the market. On the other hand, higher cost of devices and availability of alternative devices may hamper the growth of the market during the forecast period.

Global Needle-Free Diabetes Care Market Is Expected to grow at a CAGR of 7.5% during the forecast period 2017-2023.

Key Players for Global Needle-Free Diabetes Care Market

Some of the major players in the global Needle-Free Diabetes Care market: Antares Pharma, Inc. (US), Bioject Medical Technologies Inc. (US), Endo International plc (US), European Pharma Group (Netherland), PharmaJet (US), Medical International Technology, Inc. (US), Valeritas, Inc. (US), PenJet Corporation (US), INJEX Pharma AG (Germany), National Medical Products Inc. (US), Crossject SA (France), Zogenix, Inc. (US), 3M Company (US).

The global Needle-Free Diabetes Care market is highly fragmented due to the presence of a number multinational and local players. The prominent players in the market adopt various strategies such as new product launch, product innovation, and investment in research and development for the advancement of needle-free devices. Some companies have adopted developmental strategies like merger and acquisition to sustain in the competitive market environment.

Antares Pharma Inc., headquartered in the US, is a specialty pharmaceutical company, which focuses on the development of new medical devices. Twin-Jector EZ II and ZOMA-Jet are the most common needle-free injector. Also, the company has got approval for Vision, which is a reusable needle-free injectors, and disposable multi-use pen injectors.

INJEX Pharma AG, German headquartered company, is a manufacturer of syringes without a needle. In 2007, INJEX Pharma AG announced FDA clearance to market and sold their needle free injection products in the America.

Regional Analysis for Global Needle-Free Diabetes Care Market

The global Needle-Free Diabetes Care market is segmented: America, Europe, Asia Pacific and the Middle East and Africa. America accounts for the largest Needle-Free Diabetes Care market. According to American Diabetic Association, 29 million Americans were suffering from diabetes in 2016, which is 9.3% of total American population. Obese patients are more prone to diabetes; increasing number of obese population in America is the major driving factor in the growth of the market. Europe is the second largest market, which is followed by Asia Pacific. Increasing awareness among the people and government support for the research and development have encouraged the growth of the market in Europe. Asia Pacific is the fastest growing Needle-Free Diabetes Care market globally. China and India contribute a major share in the Asia Pacific needle-free diabetes care market due to the presence of huge diabetic population. The Middle East & Africa holds the lowest share in the global Needle-Free Diabetes Care market.

To Browse Complete Report visit

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Market Research Future
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India
Phone: +1 646 845 9312

Release ID: 431783